Connect with us

Life Sciences

Genes & Cancer | Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer

BUFFALO, NY- December 9, 2022 – A new research paper was published in Genes & Cancer on November 23, 2022, entitled, “Ectopic expression of lncRNA…

Published

on

This article was originally published by BioEngineering

BUFFALO, NY- December 9, 2022 – A new research paper was published in Genes & Cancer on November 23, 2022, entitled, “Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer.”

Figure 1

Credit: 2022 Ghanbari et al.

BUFFALO, NY- December 9, 2022 – A new research paper was published in Genes & Cancer on November 23, 2022, entitled, “Ectopic expression of lncRNA MVIH as a potential diagnostic biomarker in cervical cancer.”

Cervical cancer (CC) is one of the most common cancers in women. Recent advances in screening and vaccination against the papilloma virus (HPV) have increased protection against CC. However, there is no effective diagnostic biomarker and treatment approach during the course of the disease.

In this new study, researchers Mohammad Ghanbari, Aida Aghazadeh, Elaheh Malekabbaslou, Ali Rajabi, Aref Sobhkhizy, Melika Maydanchi, Ali Saber, and Reza Safaralizadeh from the University of Tabriz and Zimagene Medical Genetics Laboratory aimed to evaluate the changes in the expression of lncRNA associated with microvascular invasion in hepatocellular carcinoma (lncRNA MVIH) and its diagnostic value as a biomarker in CC patients.

“This research is aimed to evaluate the expression levels of MVIH in CC tumors to assess the potential of this lncRNA as a diagnostic biomarker in CC patients.”

One-hundred and fifteen (n = 115) pairs of CC primary tumor and marginal non-tumor tissue samples were obtained from Tabriz Valiasr International Hospital (Tabriz, Iran). RNA extraction and cDNA synthesis followed by quantitative reverse transcriptase PCR (qRT-PCR) were considered to investigate alterations in the expression levels of MVIH in patients with CC. The associations between MVIH expression changes and clinicopathological features as well as its potential as a diagnostic biomarker were assessed using SPSS and GraphPad prism software and the receiver operating characteristic (ROC).

The expression levels of MVIH were significantly higher in CC tumors as compared to marginal non-tumor samples (p

“Overexpression of MVIH in CC tumors suggests its oncogenic role during tumorigenesis. Thus, it may serve as a potential diagnostic biomarker.”
 

Read the full research paper: DOI: https://doi.org/10.18632/genesandcancer.224  

Correspondence: Reza Safaralizadeh Email: safaralizadeh@tabrizu.ac.ir 

Keywords: MVIH; lncRNA; non-coding RNA; biomarker; cervical cancer

 

About Genes & Cancer: Genes & Cancer covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, their role in signal transduction and the mechanisms by which their expression and function are altered during tumor development. In addition to publishing manuscripts that directly relate to these areas of research, Genes & Cancer also aims to attract papers in the areas of genomics, drug development and systems biology.

To learn more about Genes & Cancer, visit www.genesandcancer.com and connect with us on social media:

  • Twitter
  • Facebook
  • YouTube
  • LinkedIn
  • Instagram

 

For media inquiries, please contact: media@impactjournals.com.

 

Genes & Cancer Journal Office

6666 East Quaker Str., Suite 1C

Orchard Park, NY 14127

Phone: 1-212-659-5400

###





Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending